Limitation or failure · Medicine

FDA opens policy discussion on AI in drug development and manufacturing

FDA opens policy discussion on AI in drug development and manufacturing: cautionary signal for reliability, quality, governance, or limits of AI in research.

Summary

FDA released two discussion papers on artificial intelligence and machine learning in drug development and drug manufacturing. The agency framed AI/ML as relevant to therapeutic development, manufacturing, evaluation and clinical-trial or adverse-event workflows, while raising issues such as cybersecurity, bias, opacity and risk management.

AI role

AI systems or AI-enabled research workflows are evaluated for reliability, rigor, trust, quality, or failure modes in medicine.

Narrative role

This qualifies the acceleration story by documenting reliability, rigor, governance, quality, or failure modes that can weaken simple progress narratives.

Caveat

This identifies a limitation or risk and should be connected to specific downstream effects before generalizing.